---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060210"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:04:11.229150+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q3 net loss $33.3M; FDA backs registrational path for BA3011 in NSCLC

## Summary
- Net loss widened to $33.3M in Q3 2023 from $25.8M a year ago, driven by a 43% rise in R&D costs.
- Cash fell to $141.3M at Sep 30, down from $215.5M at Dec 31 2022; now expected to fund operations into 2H 2025.
- FDA supportive of registrational path for CAB-AXL-ADC (BA3011) in NSCLC; detailed Phase 2 data to be presented in early December.
- New partial responses observed with CAB-ROR2-ADC (BA3021) in melanoma and head & neck cancer at Phase 2.
- Phase 2 for CAB-CTLA-4 (BA3071) initiated with first patient in; Phase 1 data and R&D Day on Dec 13.

## SEC filing metadata
- accession: 0000950170-23-060210
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/0000950170-23-060210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/bcab-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060210
- JSON: https://secwatch.observer/filing/0000950170-23-060210.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060210.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017023060210/0000950170-23-060210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.